DK3512857T3 - Spiro-bicykliske inhibitorer af menin-mll-interaktion - Google Patents
Spiro-bicykliske inhibitorer af menin-mll-interaktion Download PDFInfo
- Publication number
- DK3512857T3 DK3512857T3 DK17768428.9T DK17768428T DK3512857T3 DK 3512857 T3 DK3512857 T3 DK 3512857T3 DK 17768428 T DK17768428 T DK 17768428T DK 3512857 T3 DK3512857 T3 DK 3512857T3
- Authority
- DK
- Denmark
- Prior art keywords
- menin
- spiro
- mll interaction
- bicyclic inhibitors
- bicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662394295P | 2016-09-14 | 2016-09-14 | |
| EP16192431 | 2016-10-05 | ||
| PCT/EP2017/073004 WO2018050686A1 (en) | 2016-09-14 | 2017-09-13 | Spiro bicyclic inhibitors of menin-mll interaction |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| DK3512857T3 true DK3512857T3 (da) | 2021-05-10 |
Family
ID=59895299
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| DK17768428.9T DK3512857T3 (da) | 2016-09-14 | 2017-09-13 | Spiro-bicykliske inhibitorer af menin-mll-interaktion |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11220517B2 (da) |
| EP (1) | EP3512857B1 (da) |
| JP (1) | JP6975791B2 (da) |
| KR (1) | KR102493644B1 (da) |
| CN (1) | CN109689663B (da) |
| AU (1) | AU2017326487B2 (da) |
| BR (1) | BR112019004691A2 (da) |
| DK (1) | DK3512857T3 (da) |
| ES (1) | ES2872003T3 (da) |
| HR (1) | HRP20210514T1 (da) |
| HU (1) | HUE053907T2 (da) |
| IL (1) | IL265233B (da) |
| LT (1) | LT3512857T (da) |
| MX (1) | MX2019002962A (da) |
| SI (1) | SI3512857T1 (da) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US12084462B2 (en) | 2016-09-14 | 2024-09-10 | Janssen Pharmaceutica Nv | Spiro bicyclic inhibitors of menin-MLL interaction |
| SI3512857T1 (sl) | 2016-09-14 | 2021-07-30 | Janssen Pharmaceutica Nv | Spiro biciklični zaviralci interakcije menin-MLL |
| AU2017326485B2 (en) * | 2016-09-14 | 2021-04-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-MLL interaction |
| MX2019007067A (es) | 2016-12-15 | 2019-10-15 | Janssen Pharmaceutica Nv | Inhibidores de azepano de la interacción menina-mll. |
| US11396517B1 (en) | 2017-12-20 | 2022-07-26 | Janssen Pharmaceutica Nv | Exo-aza spiro inhibitors of menin-MLL interaction |
| CN112812584A (zh) * | 2019-11-16 | 2021-05-18 | 复旦大学 | 一种含氮杂环丁烷螺环结构的荧光染料及其制备方法和应用 |
| CN118255774A (zh) * | 2019-12-19 | 2024-06-28 | 詹森药业有限公司 | 取代的直链螺环衍生物 |
| CN114478568A (zh) * | 2020-10-27 | 2022-05-13 | 苏州优理生物医药科技有限公司 | 一种噻吩并嘧啶类化合物、包含其药物组合物及其应用 |
| CN114516873A (zh) * | 2020-11-18 | 2022-05-20 | 苏州优理生物医药科技有限公司 | 一种螺环类化合物、包含其药物组合物及其应用 |
| CN116903609A (zh) * | 2021-11-05 | 2023-10-20 | 上海优理惠生医药有限公司 | 一种化合物、包含其的药物组合物及其应用 |
| WO2023244870A1 (en) * | 2022-06-17 | 2023-12-21 | INSTITUTE FOR CANCER RESEARCH d.b.a THE RESEARCH INSTITUTE OF FOX CHASE CANCER CENTER | Compositions and methods for control of transient site-specific copy gains, genomic insertions, and rearrangements associated with mixed lineage leukemia |
Family Cites Families (48)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6143749A (en) | 1995-06-07 | 2000-11-07 | Abbott Laboratories | Heterocyclic substituted cyclopentane compounds |
| PL372145A1 (en) | 2002-02-19 | 2005-07-11 | Cv Therapeutics, Inc. | Partial and full agonists of a sb 1 /sb adenosine receptors |
| US20040043959A1 (en) | 2002-03-04 | 2004-03-04 | Bloom Laura A. | Combination therapies for treating methylthioadenosine phosphorylase deficient cells |
| AU2003299249B2 (en) | 2002-12-23 | 2010-05-27 | Janssen Pharmaceutica N.V. | Substituted 1-piperidin-4-yl-4-azetidin-3-yl-piperazine derivatives and their use as neurokinin antagonists |
| US7612078B2 (en) | 2003-03-31 | 2009-11-03 | Epix Delaware, Inc. | Piperidinylamino-thieno[2,3-D] pyrimidine compounds |
| MXPA06013250A (es) | 2004-05-14 | 2007-02-28 | Abbott Lab | Inhibidores de quinasa como agentes terapeuticos. |
| JP4545196B2 (ja) | 2005-01-19 | 2010-09-15 | メルク・シャープ・エンド・ドーム・コーポレイション | 有糸分裂キネシン阻害剤 |
| GB0713602D0 (en) | 2007-07-12 | 2007-08-22 | Syngenta Participations Ag | Chemical compounds |
| TWI389913B (zh) | 2008-09-08 | 2013-03-21 | Lg Life Sciences Ltd | 并合雜環化合物 |
| JP5343975B2 (ja) | 2008-10-06 | 2013-11-13 | 日本電気株式会社 | 無線通信装置、無線通信システム、無線通信装置の制御方法、及びプログラム |
| JP2011026305A (ja) | 2009-06-24 | 2011-02-10 | Daiichi Sankyo Co Ltd | イミダゾールカルボニル化合物を含有する医薬組成物 |
| ES2468794T3 (es) * | 2009-08-20 | 2014-06-17 | Bayer Cropscience Ag | Derivados de sulfuro sustituidos con 3-triazolilfenilo como acaricidas e insecticidas |
| CA2773131C (en) | 2009-09-04 | 2015-07-14 | The Regents Of The University Of Michigan | Compositions and methods for treatment of leukemia |
| JP2013533868A (ja) * | 2010-07-09 | 2013-08-29 | レオ ファーマ アクティーゼルスカブ | タンパク質チロシンキナーゼ阻害剤としての新規ホモピペラジン誘導体およびそれらの医薬使用 |
| CA2819625A1 (en) | 2010-12-03 | 2012-06-07 | Epizyme, Inc. | 7-deazapurine modulators of histone methyltransferase, and methods of use thereof |
| WO2012082436A2 (en) | 2010-12-03 | 2012-06-21 | Epizyme, Inc. | Modulators of histone methyltransferase, and methods of use thereof |
| WO2013018404A1 (ja) | 2011-08-01 | 2013-02-07 | オリンパスメディカルシステムズ株式会社 | 挿入部形状表示装置 |
| WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
| CN103664991B (zh) | 2012-09-19 | 2016-12-28 | 中国科学院福建物质结构研究所 | 噻吩[2,3‑d]嘧啶衍生物、其制备方法及其用途 |
| MX2015006191A (es) * | 2012-11-16 | 2015-08-10 | Merck Sharp & Dohme | Inhibidores de purina de fosfatidilinositol 3-quinasa delta humana. |
| PT2935222T (pt) | 2012-12-21 | 2018-12-10 | Epizyme Inc | Inibidores de prmt5 e seus usos |
| WO2014100695A1 (en) | 2012-12-21 | 2014-06-26 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| US8940726B2 (en) | 2012-12-21 | 2015-01-27 | Epizyme, Inc. | PRMT5 inhibitors and uses thereof |
| WO2014164543A1 (en) * | 2013-03-13 | 2014-10-09 | The Regents Of The University Of Michigan | Compositions comprising thienopyrimidine and thienopyridine compounds and methods of use thereof |
| WO2015171738A2 (en) * | 2014-05-06 | 2015-11-12 | The Procter & Gamble Company | Fragrance compositions |
| WO2015191701A1 (en) | 2014-06-10 | 2015-12-17 | The Trustees Of The University Of Pennsylvania | Scaffolds for inhibitors of menin-mll interactions |
| WO2015200680A2 (en) | 2014-06-25 | 2015-12-30 | Epizyme, Inc. | Prmt5 inhibitors and uses thereof |
| WO2016040330A1 (en) | 2014-09-09 | 2016-03-17 | The Regents Of The University Of Michigan | Thienopyrimidine and thienopyridine compounds and methods of use thereof |
| WO2016081732A1 (en) | 2014-11-19 | 2016-05-26 | Memorial Sloan-Kettering Cancer Center | Thienopyrimidines and uses thereof |
| CN105732636B (zh) | 2014-12-30 | 2020-04-21 | 广东东阳光药业有限公司 | 杂芳化合物及其在药物中的应用 |
| UA118315C2 (uk) | 2015-02-24 | 2018-12-26 | Пфайзер Інк. | Заміщені нуклеозидні похідні, прийнятні як протиракові агенти |
| US10588907B2 (en) | 2015-06-04 | 2020-03-17 | Kura Oncology, Inc. | Methods and compositions for inhibiting the interaction of menin with MLL proteins |
| TWI703150B (zh) | 2015-06-04 | 2020-09-01 | 美商庫拉腫瘤技術股份有限公司 | 用於抑制ｍｅｎｉｎ及ｍｌｌ蛋白之交互作用的方法及組合物 |
| TWI730980B (zh) | 2015-08-26 | 2021-06-21 | 比利時商健生藥品公司 | 使用作為ｐｒｍｔ５抑制劑之新穎經６-６雙環芳香環取代之核苷類似物 |
| JP2018538330A (ja) * | 2015-12-22 | 2018-12-27 | ヴァイティー ファーマシューティカルズ，インコーポレイテッド | ｍｅｎｉｎ−ＭＬＬ相互作用の阻害剤 |
| EP3429585B1 (en) | 2016-03-16 | 2021-11-24 | Kura Oncology, Inc. | Bridged bicyclic inhibitors of menin-mll and methods of use |
| HRP20230537T1 (hr) | 2016-03-16 | 2023-08-04 | Kura Oncology, Inc. | Supstituirani derivati tieno[2,3-d]pirimidina kao inhibitori za menin-mll i postupci za uporabu |
| BR112018072570A2 (pt) | 2016-05-02 | 2019-02-19 | Univ Michigan Regents | piperidinas como inibidores de menina |
| WO2017207387A1 (en) * | 2016-05-31 | 2017-12-07 | Bayer Pharma Aktiengesellschaft | Spiro condensed azetidine derivatives as inhibitors of the menin-mml1 interaction |
| CN109743875B (zh) | 2016-06-10 | 2022-04-29 | 生命医药有限责任公司 | Menin-mll相互作用的抑制剂 |
| WO2018024602A1 (en) * | 2016-08-04 | 2018-02-08 | Bayer Aktiengesellschaft | 2,7-diazaspiro[4.4]nonanes |
| KR102339881B1 (ko) | 2016-09-06 | 2021-12-14 | 가부시끼가이샤 쓰리본드 | 열경화형 도전성 접착제 |
| SI3512857T1 (sl) | 2016-09-14 | 2021-07-30 | Janssen Pharmaceutica Nv | Spiro biciklični zaviralci interakcije menin-MLL |
| TWI738864B (zh) | 2016-09-14 | 2021-09-11 | 比利時商健生藥品公司 | Ｍｅｎｉｎ-ｍｌｌ相互作用之螺二環抑制劑 |
| AU2017326485B2 (en) | 2016-09-14 | 2021-04-22 | Janssen Pharmaceutica Nv | Fused bicyclic inhibitors of menin-MLL interaction |
| AU2017326006B2 (en) | 2016-09-16 | 2021-10-28 | Vitae Pharmaceuticals, LLC. | Inhibitors of the menin-MLL interaction |
| EA201991448A1 (ru) | 2017-01-06 | 2019-12-30 | Янссен Фармацевтика Нв | Азепановые ингибиторы взаимодействия менин-mll |
| CN110691779B (zh) | 2017-03-24 | 2023-10-10 | 库拉肿瘤学公司 | 治疗血液系统恶性肿瘤和尤因肉瘤的方法 |
-
2017
- 2017-09-13 SI SI201730700T patent/SI3512857T1/sl unknown
- 2017-09-13 DK DK17768428.9T patent/DK3512857T3/da active
- 2017-09-13 CN CN201780056188.3A patent/CN109689663B/zh active Active
- 2017-09-13 BR BR112019004691A patent/BR112019004691A2/pt unknown
- 2017-09-13 MX MX2019002962A patent/MX2019002962A/es unknown
- 2017-09-13 US US16/331,606 patent/US11220517B2/en active Active
- 2017-09-13 HU HUE17768428A patent/HUE053907T2/hu unknown
- 2017-09-13 EP EP17768428.9A patent/EP3512857B1/en active Active
- 2017-09-13 LT LTEP17768428.9T patent/LT3512857T/lt unknown
- 2017-09-13 AU AU2017326487A patent/AU2017326487B2/en active Active
- 2017-09-13 ES ES17768428T patent/ES2872003T3/es active Active
- 2017-09-13 JP JP2019535974A patent/JP6975791B2/ja active Active
- 2017-09-13 KR KR1020197008627A patent/KR102493644B1/ko active IP Right Grant
-
2019
- 2019-03-07 IL IL265233A patent/IL265233B/en active IP Right Grant
-
2021
- 2021-03-30 HR HRP20210514TT patent/HRP20210514T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019532100A (ja) | 2019-11-07 |
| KR102493644B1 (ko) | 2023-01-30 |
| IL265233B (en) | 2021-06-30 |
| EP3512857A1 (en) | 2019-07-24 |
| ES2872003T3 (es) | 2021-11-02 |
| SI3512857T1 (sl) | 2021-07-30 |
| IL265233A (en) | 2019-05-30 |
| AU2017326487A1 (en) | 2019-02-28 |
| HRP20210514T1 (hr) | 2021-05-14 |
| KR20190045242A (ko) | 2019-05-02 |
| JP6975791B2 (ja) | 2021-12-01 |
| HUE053907T2 (hu) | 2021-07-28 |
| CN109689663B (zh) | 2023-04-14 |
| US11220517B2 (en) | 2022-01-11 |
| LT3512857T (lt) | 2021-04-12 |
| US20190211036A1 (en) | 2019-07-11 |
| AU2017326487B2 (en) | 2021-08-05 |
| MX2019002962A (es) | 2019-07-04 |
| BR112019004691A2 (pt) | 2019-06-25 |
| EP3512857B1 (en) | 2021-02-24 |
| CN109689663A (zh) | 2019-04-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DK3512850T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3468966T3 (da) | Inhibitorer af menin-mll-interaktionen | |
| DK3102576T3 (da) | Dihydropyrrolopyridininhibitorer af ror-gamma | |
| DK3377059T3 (da) | Hæmmere af cxcr2 | |
| DK3371171T3 (da) | Inhibitorer af RET | |
| DK3512857T3 (da) | Spiro-bicykliske inhibitorer af menin-mll-interaktion | |
| DK3160956T3 (da) | Inhibitorer af lysin-specifik demethylase-1 | |
| DK3164380T3 (da) | Hæmmere af lysinspecifik demethylase-1 | |
| DK3137169T3 (da) | Hæmmere af lysin-specifik demethylase-1 | |
| DK3509581T3 (da) | Formuleringer af (r)-2-amino-3-phenylpropylcarbamat | |
| DK3442972T3 (da) | Bromdomænehæmmere | |
| DK3192902T3 (da) | Fremgangsmåde til fremstilling af graphenholdige viscosefibre | |
| DK3466432T3 (da) | Fremgangsmåder til behandling af pulmonale non-tuberkuløse mykobakterielle infektioner | |
| DK3851537T5 (da) | Behandling af hyperbilirubinæmi | |
| DK3554240T3 (da) | Kombinationer af aktive forbindelser | |
| DK3325443T3 (da) | Fremgangsmåde til fremstilling af pridopidin | |
| DK3317400T3 (da) | Fremgangsmåde til kryokonservering af tumorinfiltrerende lymfocytter | |
| DK3244891T3 (da) | Forbindelser til forbedring af mrna-splejsning | |
| DK3180331T3 (da) | Polymorfer af selinexor | |
| DK3551625T3 (da) | Heterocykliske inhibitorer af mct4 | |
| DK3368683T3 (da) | Fremgangsmåde til kvantifikationen af pd-l1 | |
| DK3261726T3 (da) | Sammensætning til behandling af acne | |
| DK3143026T3 (da) | Forbindelser og sammensætninger til induktion af chondrogenese | |
| DK3371165T3 (da) | Btk-inhibitor til anvendelse til behandling af kræft | |
| DK3457851T3 (da) | Derivater af sobetirom |